Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Racial Differences in Phosphorus Metabolism

This study has been completed.
National Institutes of Health (NIH)
Information provided by:
University of Miami Identifier:
First received: March 4, 2009
Last updated: June 30, 2011
Last verified: September 2010
The investigators aim to study potential racial differences in renal phosphorus handling by provocatively testing urinary phosphorus excretion using parathyroid hormone infusions in healthy white volunteers compared to healthy black volunteers.

Condition Intervention
Healthy Volunteers
Drug: 1-34 parathyroid infusion

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Racial Differences in Phosphorus Metabolism

Resource links provided by NLM:

Further study details as provided by University of Miami:

Primary Outcome Measures:
  • Urinary phosphorus excretion [ Time Frame: six hours ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: February 2009
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: 1-34 parathyroid infusion
    1-34 parathyroid infusion at 0.055 mcg/kg/hr for 6 hours

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 18 years of age or older
  • Body mass index (BMI) within 20% ideal for their age and gender

Exclusion Criteria:

  • Abnormal urinalysis
  • Pregnancy or breast-feeding
  • Medical conditions impacting phosphorus metabolism—primary hyperparathyroidism; diabetes mellitus; gastrointestinal malabsorption disorders; hyper- or hypothyroidism
  • Medications known to affect phosphorus metabolism— current use of phosphorus supplements, phosphorus binders, calcitriol or calcitriol analogues, regular antacid or laxative use, calcitonin, etidronate, anticonvulsants
  • Hyper- or hypophosphatemia (≥ 4.6 mg/dl or ≤ 2.5 mg/dl respectively), hyper- or hypocalcemia (≥ 10.6 or ≤ 8.5 mg/dl respectively), or severe anemia (Hgb < 8 g/dl for women and < 9 g/dl for men)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00856726

United States, Florida
University of Miami
Miami, Florida, United States, 33136
Sponsors and Collaborators
University of Miami
National Institutes of Health (NIH)
Principal Investigator: Orlando M Gutierrez, MD, MMSc University of Miami
  More Information

Responsible Party: Orlando M. Gutierrez, MD, MMSc, University of Miami Identifier: NCT00856726     History of Changes
Other Study ID Numbers: 20080669  K23DK081673 
Study First Received: March 4, 2009
Last Updated: June 30, 2011
Health Authority: United States: Food and Drug Administration processed this record on October 21, 2016